Takahiro Kasamatsu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Takahiro Kasamatsu has a total of 172 co-authors. Here are the top co-authors by number of shared publications:
- Takashi Onda
Department of Gynecology, Kitasato University School of Medicine, Sagamihara, Japan
4 shared publications - Tomoyasu Kato
Department of Gynecology, National Cancer Center Hospital, Tokyo, Japan
4 shared publications - Mitsuya Ishikawa
Department of Gynecology, National Cancer Center Hospital, Tokyo, Japan
3 shared publications - Noriyuki Katsumata
Department of Medical Oncology, Nippon Medical School Musashikosugi Hospital, Kawasaki, Japan
3 shared publications - Shin Nishio
Department of Obstetrics and Gynecology, Kurume University School of Medicine, Fukuoka, Japan
3 shared publications - Yasuhiro Fujiwara
Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
3 shared publications
Latest Publications
- Open Access
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
A confirmatory trial of hysterectomy with minimal parametrectomy for stage IB1 cervical cancer involving a tumor diameter of 2 cm or less: a Japan Clinical Oncology Group study (JCOG1101)
Arimoto T, et al. J Gynecol Oncol. 2027 ;38:e8. https://doi.org/10.3802/jgo.2027.38.e8
- 1 January 2027
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 38
Open AccessA confirmatory trial of hysterectomy with minimal parametrectomy for stage IB1 cervical cancer involving a tumor diameter of 2 cm or less: a Japan Clinical Oncology Group study (JCOG1101)
Arimoto T, et al. J Gynecol Oncol. 2027 ;38:e8. https://doi.org/10.3802/jgo.2027.38.e8
- 31 January 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 51 (6) , 109669
Validation of the Japan Clinical Oncology Group postoperative complications criteria against CTCAE for evaluation of postoperative complications (JCOG1903A)
- 31 January 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 51 (6) , 109669
Validation of the Japan Clinical Oncology Group postoperative complications criteria against CTCAE for evaluation of postoperative complications (JCOG1903A)
- Open Access
- 1 January 2023
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 34 (3)
Phase I/II prospective clinical trial for the hybrid of intracavitary and interstitial brachytherapy for locally advanced uterine cervical cancer
Murakami N, et al. J Gynecol Oncol. 2022 Dec;34:e24. https://doi.org/10.3802/jgo.2023.34.e24
- 1 January 2023
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 34 (3)
Open AccessPhase I/II prospective clinical trial for the hybrid of intracavitary and interstitial brachytherapy for locally advanced uterine cervical cancer
Murakami N, et al. J Gynecol Oncol. 2022 Dec;34:e24. https://doi.org/10.3802/jgo.2023.34.e24
- Open Access
- 1 May 2021
- Published by Elsevier in Redox Biology
- Vol. 41, 101926
On-tissue polysulfide visualization by surface-enhanced Raman spectroscopy benefits patients with ovarian cancer to predict post-operative chemosensitivity
- 1 May 2021
- Published by Elsevier in Redox Biology
- Vol. 41, 101926
Open AccessOn-tissue polysulfide visualization by surface-enhanced Raman spectroscopy benefits patients with ovarian cancer to predict post-operative chemosensitivity
- 20 May 2018
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 36 (15_suppl) , 5527
Propensity score-matched analysis of systemic chemotherapy versus hysterectomy for patients with residual cervical disease after definitive radiotherapy/concurrent chemoradiotherapy.
5527 Background: Patients with persistent cervical cancer after definitive radiotherapy/concurrent chemoradiotherapy (RT/CCRT) have a poor prognosis. Salvage hysterectomy (HT) is considered curative treatment; however, very little data exists showing the survival advantage of HT over standard therapy. Methods: Patients with persistent cervical cancer treated with definitive RT/CCRT at 35 institutions from 2005–2014 were reviewed retrospectively. Those who underwent a HT for residual cervical disease after definitive RT/CCRT were matched (histology, FIGO stage at initial treatment, brachytherapy application, age and performance status at diagnosis of residual tumor, diameter and parametrial invasion by residual tumor, and the number of lymph node tumors at diagnosis, etc.) with propensity scores for patients who underwent systemic chemotherapy (CT). Oncologic outcomes between the two groups using a propensity score matched–cohort analysis were compared. Results: A total of 142 patients with residual cervical disease after definitive RT/CCRT were included after matching (HT: 71, systemic CT: 71). A difference in all background factors between HT and CT groups was not observed. At a median follow-up of 4.6 years, 33 (46.5%) and 47 deaths (66.2%) occurred in HT and CT groups, respectively. Median overall survival was 3.8 and 1.5 years in HT and CT groups, respectively (p= 0.0019, hazards ratio [HR] 2.438, 95% confidence interval [CI] 1.362–4.361), and median progression-free survival was 2.7 and 0.7 years, respectively (p= 0.0046, HR 2.235, 95% CI 1.262–3.960). Increasing tumor size was significantly associated with a high incomplete resection rate (p= 0.0385, Odds Ratio 0.941, 95% CI 0.888–0.997). The cut-off value for the residual tumor diameter regarding complete resection after receiver operating characteristic (ROC) analysis was 11 mm (sensitivity 70%, specificity 86.9%). Conclusions: Salvage HT may be considered curative treatment for patients with residual cervical disease after definitive RT/CCRT. The diameter of residual tumor is important in selecting appropriate candidates for HT.
- 20 May 2018
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 36 (15_suppl) , 5527
Propensity score-matched analysis of systemic chemotherapy versus hysterectomy for patients with residual cervical disease after definitive radiotherapy/concurrent chemoradiotherapy.
5527 Background: Patients with persistent cervical cancer after definitive radiotherapy/concurrent chemoradiotherapy (RT/CCRT) have a poor prognosis. Salvage hysterectomy (HT) is considered curative treatment; however, very little data exists showing the survival advantage of HT over standard therapy. Methods: Patients with persistent cervical cancer treated with definitive RT/CCRT at 35 institutions from 2005–2014 were reviewed retrospectively. Those who underwent a HT for residual cervical disease after definitive RT/CCRT were matched (histology, FIGO stage at initial treatment, brachytherapy application, age and performance status at diagnosis of residual tumor, diameter and parametrial invasion by residual tumor, and the number of lymph node tumors at diagnosis, etc.) with propensity scores for patients who underwent systemic chemotherapy (CT). Oncologic outcomes between the two groups using a propensity score matched–cohort analysis were compared. Results: A total of 142 patients with residual cervical disease after definitive RT/CCRT were included after matching (HT: 71, systemic CT: 71). A difference in all background factors between HT and CT groups was not observed. At a median follow-up of 4.6 years, 33 (46.5%) and 47 deaths (66.2%) occurred in HT and CT groups, respectively. Median overall survival was 3.8 and 1.5 years in HT and CT groups, respectively (p= 0.0019, hazards ratio [HR] 2.438, 95% confidence interval [CI] 1.362–4.361), and median progression-free survival was 2.7 and 0.7 years, respectively (p= 0.0046, HR 2.235, 95% CI 1.262–3.960). Increasing tumor size was significantly associated with a high incomplete resection rate (p= 0.0385, Odds Ratio 0.941, 95% CI 0.888–0.997). The cut-off value for the residual tumor diameter regarding complete resection after receiver operating characteristic (ROC) analysis was 11 mm (sensitivity 70%, specificity 86.9%). Conclusions: Salvage HT may be considered curative treatment for patients with residual cervical disease after definitive RT/CCRT. The diameter of residual tumor is important in selecting appropriate candidates for HT.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e17074
Accuracy of preoperative imaging diagnosis as a possible new staging system in advanced ovarian, tubal, and peritoneal cancer: Using data from Japan Clinical Oncology Group study JCOG0602.
E17074Background: We need a new staging system by preoperative imaging diagnosis when neoadjuvant chemotherapy (NAC) setting treatment becomes a standard treatment for advanced ovarian, tubal and peritoneal cancers. The purpose is to know whether we can accurately diagnose the origin and stage of cancer without diagnostic surgery before NAC. Methods: Preoperative institutional imaging diagnosis (IDx) for origin and tumor spread were compared with surgical or pathological findings in primary debulking surgery (PDS) in randomized controlled trial comparing between PDS and NAC arms in stage III/IV ovarian, tubal and peritoneal cancers (JCOG0602). These cancers were diagnosed preoperatively by 1) imaging studies (CT and/or MRI), 2) cytology of ascites, pleural effusions or fluids obtained by tumor centesis, and 3) CA125 > 200 U/ml and CEA < 20 ng/ml. Accuracy of IDx to diagnose extra-pelvic peritoneal tumor (EPT) and retroperitoneal lymph node metastasis (LNM), and to distinguish between ≤ 2cm and > 2cm EPT w...
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e17074
Accuracy of preoperative imaging diagnosis as a possible new staging system in advanced ovarian, tubal, and peritoneal cancer: Using data from Japan Clinical Oncology Group study JCOG0602.
E17074Background: We need a new staging system by preoperative imaging diagnosis when neoadjuvant chemotherapy (NAC) setting treatment becomes a standard treatment for advanced ovarian, tubal and peritoneal cancers. The purpose is to know whether we can accurately diagnose the origin and stage of cancer without diagnostic surgery before NAC. Methods: Preoperative institutional imaging diagnosis (IDx) for origin and tumor spread were compared with surgical or pathological findings in primary debulking surgery (PDS) in randomized controlled trial comparing between PDS and NAC arms in stage III/IV ovarian, tubal and peritoneal cancers (JCOG0602). These cancers were diagnosed preoperatively by 1) imaging studies (CT and/or MRI), 2) cytology of ascites, pleural effusions or fluids obtained by tumor centesis, and 3) CA125 > 200 U/ml and CEA < 20 ng/ml. Accuracy of IDx to diagnose extra-pelvic peritoneal tumor (EPT) and retroperitoneal lymph node metastasis (LNM), and to distinguish between ≤ 2cm and > 2cm EPT w...
- 9 June 2011
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 37 (11) , 1706-1710
Primary extraskeletal myxoid chondrosarcoma of the vulva
Primary extraskeletal myxoid chondrosarcoma (EMC) of the vulva is extremely rare. There is little available information about the biological behavior and treatment strategy for primary EMC of the vulva. We report a rare case of primary EMC of the vulva treated surgically. A 24‐year‐old Japanese woman had demonstrated a small and elastic mass of the vulva and underwent enucleation of the mass at a previous hospital, but a definitive histopathological diagnosis was not obtained. Therefore, the patient was referred to our hospital for further evaluation and treatment. We histopathologically diagnosed the tumor as primary EMC of the vulva and performed vulvectomy with vulvoperineal reconstruction. Microscopic examination of the resected specimens demonstrated residual tumor nodules of EMC. However, there were no viable tumor cells at the surgical margin. Approximately two years after wide local excision was performed, the patient is doing well and there is no apparent recurrence of EMC.
- 9 June 2011
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 37 (11) , 1706-1710
Primary extraskeletal myxoid chondrosarcoma of the vulva
Primary extraskeletal myxoid chondrosarcoma (EMC) of the vulva is extremely rare. There is little available information about the biological behavior and treatment strategy for primary EMC of the vulva. We report a rare case of primary EMC of the vulva treated surgically. A 24‐year‐old Japanese woman had demonstrated a small and elastic mass of the vulva and underwent enucleation of the mass at a previous hospital, but a definitive histopathological diagnosis was not obtained. Therefore, the patient was referred to our hospital for further evaluation and treatment. We histopathologically diagnosed the tumor as primary EMC of the vulva and performed vulvectomy with vulvoperineal reconstruction. Microscopic examination of the resected specimens demonstrated residual tumor nodules of EMC. However, there were no viable tumor cells at the surgical margin. Approximately two years after wide local excision was performed, the patient is doing well and there is no apparent recurrence of EMC.
- 7 March 2011
- Published by Wiley in Cancer Science
- Vol. 102 (5) , 1068-1075
Novel virtual cytological analysis for the detection of endometrial cancer cells using autoscan fluoromicroscopy
The current medical examinations for detecting endometrial cancer can sometimes be stressful and inconvenient for examinees and examiners. Therefore, we attempted to develop an autoscan-virtual cytology system for detecting endometrial cancer without relying on judgment by the human eye. Exfoliated cells from the uterus were retrieved using a tampon inserted for 3 h. More than 100 monoclonal antibodies (mAb) developed by us were screened in three steps of immunohistochemistry to find mAb sets that would enable the cancer and normal endometrium to be perfectly distinguished. The exfoliated cells provided by 30 endometrial cancer patients and a total of 37 samples of 14 non-malignant volunteers including the menstrual cycle were analyzed using imaging cytometry. All samples contained epithelial cells and dysplasia cells, but the pathologist could not definitively diagnose all of them as endometrial cancer cells because most cells had degenerated. Twenty-two of 28 endometrial cancer tissues (79%) were positive with four mAb sets, CRELD1, GRK5, SLC25A27 and STC2, and 22 of 22 normal endometriums (100%) were negative. Our newly developed autoscan-virtual cytology for exfoliated endometrial cells showed overall sensitivity for endometrial cancer patients and overall specificity for volunteers of 50% (15/30) and 95% (35/37), respectively. Our autoscan-virtual cytology combined with cancer-specific mAb and imaging cytometry could be useful for endometrial cancer detection. Autoscan-virtual cytology for endometrial cancer deserves further evaluation for future endometrial cancer screening.
- 7 March 2011
- Published by Wiley in Cancer Science
- Vol. 102 (5) , 1068-1075
Novel virtual cytological analysis for the detection of endometrial cancer cells using autoscan fluoromicroscopy
The current medical examinations for detecting endometrial cancer can sometimes be stressful and inconvenient for examinees and examiners. Therefore, we attempted to develop an autoscan-virtual cytology system for detecting endometrial cancer without relying on judgment by the human eye. Exfoliated cells from the uterus were retrieved using a tampon inserted for 3 h. More than 100 monoclonal antibodies (mAb) developed by us were screened in three steps of immunohistochemistry to find mAb sets that would enable the cancer and normal endometrium to be perfectly distinguished. The exfoliated cells provided by 30 endometrial cancer patients and a total of 37 samples of 14 non-malignant volunteers including the menstrual cycle were analyzed using imaging cytometry. All samples contained epithelial cells and dysplasia cells, but the pathologist could not definitively diagnose all of them as endometrial cancer cells because most cells had degenerated. Twenty-two of 28 endometrial cancer tissues (79%) were positive with four mAb sets, CRELD1, GRK5, SLC25A27 and STC2, and 22 of 22 normal endometriums (100%) were negative. Our newly developed autoscan-virtual cytology for exfoliated endometrial cells showed overall sensitivity for endometrial cancer patients and overall specificity for volunteers of 50% (15/30) and 95% (35/37), respectively. Our autoscan-virtual cytology combined with cancer-specific mAb and imaging cytometry could be useful for endometrial cancer detection. Autoscan-virtual cytology for endometrial cancer deserves further evaluation for future endometrial cancer screening.
- 19 December 2009
- Published by Springer Nature in Medical Oncology
- Vol. 27 (4) , 1371-1377
Clinical characteristics and outcomes of women with stage IV endometrial cancer
Treatment strategies for patients with stage IV endometrial cancer (EC) remain controversial. Some studies have suggested that optimal cytoreduction improves survival. We retrospectively analyzed the clinical characteristics and outcomes of 41 women with stage IV EC. The results of preoperative cytologic evaluation and biopsy of the endometrium were reviewed by a single pathologist for patients in whom stage IV EC was diagnosed preoperatively. Of the 41 patients with stage IV EC (median age, 62 years), 31 had surgical stage IV disease and 10 had clinical stage IV disease. Twenty-eight patients were diagnosed of stage IV EC before surgery or without surgery. Progression-free survival and overall survival were 10.4 and 21.3 months, respectively. On univariate analysis, grade 1 or 2 endometrioid subtype, 0 or 1 sites of extraperitoneal metastasis, and hormonal therapy were associated with good outcomes. Multivariate analysis revealed that grade 1 or 2 endometrioid subtype (P = 0.005, hazard ratio [HR] 0.23 [0.08–0.65]) and 0 or 1 sites of extraperitoneal metastasis (P = 0.001, HR 0.24 [0.10–0.57]) were independent predictors of survival. Neither surgery as primary therapy nor optimal cytoreduction was significantly related to overall survival in either the 28 patients in whom stage IV was diagnosed preoperatively or in all 41 patients. In women with stage IV EC, histologic features and extent of disease are more important determinants of outcomes than any kind of treatment. The indication for surgery should be carefully considered in this subset of patients.
- 19 December 2009
- Published by Springer Nature in Medical Oncology
- Vol. 27 (4) , 1371-1377
Clinical characteristics and outcomes of women with stage IV endometrial cancer
Treatment strategies for patients with stage IV endometrial cancer (EC) remain controversial. Some studies have suggested that optimal cytoreduction improves survival. We retrospectively analyzed the clinical characteristics and outcomes of 41 women with stage IV EC. The results of preoperative cytologic evaluation and biopsy of the endometrium were reviewed by a single pathologist for patients in whom stage IV EC was diagnosed preoperatively. Of the 41 patients with stage IV EC (median age, 62 years), 31 had surgical stage IV disease and 10 had clinical stage IV disease. Twenty-eight patients were diagnosed of stage IV EC before surgery or without surgery. Progression-free survival and overall survival were 10.4 and 21.3 months, respectively. On univariate analysis, grade 1 or 2 endometrioid subtype, 0 or 1 sites of extraperitoneal metastasis, and hormonal therapy were associated with good outcomes. Multivariate analysis revealed that grade 1 or 2 endometrioid subtype (P = 0.005, hazard ratio [HR] 0.23 [0.08–0.65]) and 0 or 1 sites of extraperitoneal metastasis (P = 0.001, HR 0.24 [0.10–0.57]) were independent predictors of survival. Neither surgery as primary therapy nor optimal cytoreduction was significantly related to overall survival in either the 28 patients in whom stage IV was diagnosed preoperatively or in all 41 patients. In women with stage IV EC, histologic features and extent of disease are more important determinants of outcomes than any kind of treatment. The indication for surgery should be carefully considered in this subset of patients.